NCT04724031Completed
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 180 (actual)
- First submitted
- 17 Dec 2020
- Start date
- 1 Nov 2019
- Primary completion date
- 9 Mar 2023
- Lead sponsor
- Hellenic Cooperative Oncology Group
- Diseases
- Ovarian cancer
- NCT number
- NCT04724031
What you commit to
- Study type: Observational
- Participants enrolled: 180
- From 1 Nov 2019 to the primary completion date, 9 Mar 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- \- women \>18 years old with advanced high grade ovarian cancer
Age in the registry: 18 years to 80 years · Sex: Female
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Adamantia Nikolaidi Coordinator of this site? Confirm its status | Athens | Greece | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.